Epcoritamab vs watch and wait for low tumor burden follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares the drug epcoritamab with a 'watch and wait' approach for people with low-tumor-burden follicular lymphoma who have not had treatment before. It tests whether starting treatment early with epcoritamab can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma (grades 1, 2, or 3a)
- You were diagnosed within the last 6 months and have not had lymphoma treatment
- You are 18 years or older
- Your lymphoma is stage II (non-contiguous), III, or IV
- Your disease is considered low tumor burden (small or few affected areas, no significant symptoms)
- You have measurable disease (at least one node ≥ 1.5 cm, or one outside node > 1 cm)
- You have adequate organ and bone marrow function
- You agree to use birth control and avoid donating blood or sperm during and after the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This study tests a new immunotherapy drug (epcoritamab) combined with a milder chemotherapy (rituximab-mini CVP) for older or frail patients who cannot receive standard strong chemo. It aims to effectively treat newly diagnosed diffuse large B-cell lymphoma with fewer side effects.
This trial tests a new drug (epcoritamab) given with a milder chemotherapy combination (Pola-R-mini-CHP) for people over 70 or who are not healthy enough for standard full-dose chemotherapy. The goal is to see if this approach works as well or better with fewer side effects.
Hear when a new Randomized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.